[go: up one dir, main page]

ECSP19038749A - PHARMACEUTICAL COMPLEX FORMULATION INCLUDING AMLODIPINE, LOSARTAN AND CLORTALIDONE - Google Patents

PHARMACEUTICAL COMPLEX FORMULATION INCLUDING AMLODIPINE, LOSARTAN AND CLORTALIDONE

Info

Publication number
ECSP19038749A
ECSP19038749A ECSENADI201938749A ECDI201938749A ECSP19038749A EC SP19038749 A ECSP19038749 A EC SP19038749A EC SENADI201938749 A ECSENADI201938749 A EC SENADI201938749A EC DI201938749 A ECDI201938749 A EC DI201938749A EC SP19038749 A ECSP19038749 A EC SP19038749A
Authority
EC
Ecuador
Prior art keywords
losartan
complex formulation
clortalidone
pharmaceutical complex
formulation including
Prior art date
Application number
ECSENADI201938749A
Other languages
Spanish (es)
Inventor
Yong Il Kim
Jong Soo Woo
Jae Hyun Park
Sol Ee Lim
Hyuk Jun Cho
Ho Taek Im
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62076324&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP19038749(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of ECSP19038749A publication Critical patent/ECSP19038749A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a una formulación de complejo farmacéutica que incluye amlodipina, losartán y clortalidona como ingredientes activos. La formulación de complejo farmacéutica de la presente invención que incluye amlodipina, losartán y clortalidona como ingredientes activos presenta excelentes características de disolución de los ingredientes activos, y tiene una alta uniformidad de contenido y estabilidad térmica. Por lo tanto, la formulación de complejo de la presente invención se puede usar como un agente profiláctico o terapéutico para enfermedades cardiovasculares, que tiene una excelente calidad y estabilidad térmica.The present invention relates to a pharmaceutical complex formulation that includes amlodipine, losartan and chlorthalidone as active ingredients. The pharmaceutical complex formulation of the present invention including amlodipine, losartan and chlorthalidone as active ingredients exhibits excellent dissolution characteristics of the active ingredients, and has high content uniformity and thermal stability. Therefore, the complex formulation of the present invention can be used as a prophylactic or therapeutic agent for cardiovascular diseases, which has excellent quality and thermal stability.

ECSENADI201938749A 2016-11-03 2019-05-31 PHARMACEUTICAL COMPLEX FORMULATION INCLUDING AMLODIPINE, LOSARTAN AND CLORTALIDONE ECSP19038749A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020160145518A KR101910902B1 (en) 2016-11-03 2016-11-03 Pharmaceutical complex formulation comprising amlodipine, losartan and chlorthalidone

Publications (1)

Publication Number Publication Date
ECSP19038749A true ECSP19038749A (en) 2019-06-30

Family

ID=62076324

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI201938749A ECSP19038749A (en) 2016-11-03 2019-05-31 PHARMACEUTICAL COMPLEX FORMULATION INCLUDING AMLODIPINE, LOSARTAN AND CLORTALIDONE

Country Status (12)

Country Link
KR (1) KR101910902B1 (en)
CO (1) CO2019004798A2 (en)
CR (1) CR20190264A (en)
DO (1) DOP2019000093A (en)
EA (1) EA201991107A1 (en)
EC (1) ECSP19038749A (en)
MX (1) MX2019005178A (en)
NI (1) NI201900046A (en)
PH (1) PH12019500778A1 (en)
SG (1) SG11201903145TA (en)
WO (1) WO2018084627A2 (en)
ZA (1) ZA201902718B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200143914A (en) * 2019-06-17 2020-12-28 주식회사유한양행 A pharmaceutical composition in a multi-layered tablet form comprising amlodipine or its salt and chlorthalidone its salt
KR102900997B1 (en) 2019-12-11 2025-12-22 한미약품 주식회사 Pharmaceutical complex formulation comprising amlodipine, losartan and chlorthalidone
KR20210152943A (en) 2020-06-09 2021-12-16 한미약품 주식회사 Pharmaceutical combination preparation for the prevention or treatment of cardiovascular diseases including amlodipine, losartan and chlorthalidone in a single layer tablet
MX2022015607A (en) * 2020-06-09 2023-01-24 Hanmi Pharm Ind Co Ltd Complex pharmaceutical preparation, for preventing or treating cardiovascular disease, comprising amlodipine, losartan and chlorthalidone in single-layer tablet.
GEP20247647B (en) * 2020-12-18 2024-07-25 Daewoong Pharmaceutical Co Ltd Novel formulation for oral administration, comprising 1-(5-(2,4-difluorophenyl)-1-((3-fluorophenyl) sulfonyl)-4-methoxy-1h-pyrrol-3-yl)-n-methylmethanamine
CN114705785B (en) * 2022-04-21 2023-11-07 厦门泓益检测有限公司 Method for detecting chlorophthalic acid in vegetable oil

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA012329B1 (en) * 2002-01-16 2009-08-28 Бёрингер Ингельхайм Фарма Гмбх Унд Ко. Кг Method of producing substantially amorphous telmisartan
WO2005014043A1 (en) * 2003-07-16 2005-02-17 Boehringer Ingelheim International Gmbh Chlorthalidone combinations
KR100924236B1 (en) * 2009-06-23 2009-10-29 충남대학교산학협력단 Novel manufacturing method and device for ultrafine particles having uniform particle size distribution
KR20150079373A (en) * 2013-12-30 2015-07-08 한미약품 주식회사 Composite formulation for oral administration comprising ezetimibe and rosuvastatin
KR101914930B1 (en) * 2015-03-31 2018-11-05 한미약품 주식회사 Pharmaceutical complex formulation comprising amlodipine, losartan and chlorthalidone

Also Published As

Publication number Publication date
CR20190264A (en) 2019-08-26
WO2018084627A2 (en) 2018-05-11
DOP2019000093A (en) 2019-09-30
KR20180049510A (en) 2018-05-11
CO2019004798A2 (en) 2019-05-21
SG11201903145TA (en) 2019-05-30
EA201991107A1 (en) 2019-09-30
ZA201902718B (en) 2020-08-26
NI201900046A (en) 2019-10-11
MX2019005178A (en) 2019-08-05
WO2018084627A3 (en) 2018-07-26
PH12019500778A1 (en) 2019-07-24
KR101910902B1 (en) 2018-10-24

Similar Documents

Publication Publication Date Title
ECSP19038749A (en) PHARMACEUTICAL COMPLEX FORMULATION INCLUDING AMLODIPINE, LOSARTAN AND CLORTALIDONE
CL2017003459A1 (en) Cyclic sulfamoylarylamide derivatives and their use as medicines for the treatment of hepatitis b.
CL2018000684A1 (en) Modulators of hepatitis core protein b.
CL2016002269A1 (en) Allosteric modulators of the hepatitis core protein b.
MX2019005379A (en) Pyrazolo-heteroaryl derivative, preparation method and medical use thereof.
CL2018000542A1 (en) New phenoxymethyl derivatives.
MX2016016647A (en) Method for preparing stable composition with perfume.
BR112018010720A8 (en) apelin receptor agonists and methods of use
MX386615B (en) ADENOASSORTED VIRAL VECTORS FOR THE TREATMENT OF MUCOPOLYSACCHARIDOSIS.
CO2017002472A2 (en) Abiraterone acetate formulation
CL2017001964A1 (en) Encapsulation of high power active agents.
UY37342A (en) COMBINATION OF A BCL-2 INHIBITOR AND AN MCL1 INHIBITOR, USES AND PHARMACEUTICAL COMPOSITIONS OF THESE
MX2017015462A (en) Attenuated influenza vectors for the prevention and/or treatment of infectious diseases and for the treatment of oncological diseases.
CL2018003338A1 (en) Physiologically balanced injectable formulations of fosnetupitant.
MX2017000676A (en) ORITAVANCINA HIGH PURITY AND METHOD TO PRODUCE THE SAME.
MX2017012459A (en) FORMULATION OF PHARMACEUTICAL COMPLEX THAT INCLUDES AMLODIPINA, LOSARTAN AND CLORTALIDONA.
CO2018002428A2 (en) Selected amide of gamma-hydroxyiburic acid and uses thereof in the treatment of alcohol abuse
MX2018005153A (en) IMPROVED ADHESIVE COMPOSITION.
DOP2019000015A (en) COMBINATION OF A BCL-2 INHIBITOR AND AN MCL1 INHIBITOR, USES AND PHARMACEUTICAL COMPOSITIONS OF THESE
CO2019004796A2 (en) Preparation of pharmaceutical complex comprising amlodipine, losartan and rosuvastatin
BR112016023422A8 (en) spray-dried dispersion, pharmaceutical composition and its uses, kit and tablet